Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IBIO, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| IBIO-600 | Overweight , Obesity | Phase 1 · NCT07487376 | Recruiting |
| Lasmotinib (PHI-101) | Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 · NCT04842370 | Unknown |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IBIO holds $88M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.2M/quarter from operations, an estimated runway of 42.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 35 · Moderate
The history of significant losses, the negative cash flow from operations, and the dependence by us on our ability to obtain additional financing to fund our operations in the past raised substantial doubt about our ability to continue as a going concern.10-K, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IBIO files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IBIO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →